Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: nicotinic acid Clear all
Completed Phase 3 Interventional Results available

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

NCT01004978
View directory record Official record
Conditions
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Interventions
Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Mitomycin, Pharmacological Study, Placebo Administration, Sorafenib Tosylate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
281
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 6, 2026, 9:35 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Comparative Evaluation of Nicotine Analogs

NCT07585006
View directory record Official record
Conditions
Tobacco-Related Carcinoma, Addiction
Interventions
Biospecimen Collection, Nicotine, 6-Methyl Nicotine, nicotinamide, Puffing Topography Research, Survey Administration, Cardiovascular effects
Procedure · Drug · Behavioral + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Phase 2 Interventional

Sorafenib Tosylate Before and After Hepatic Arterial Chemoembolization With Doxorubicin Hydrochloride and Mitomycin C in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

NCT00949182
View directory record Official record
Conditions
Liver Cancer
Interventions
sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C, laboratory biomarker analysis
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

NCT04514510
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Isoquercetin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 6, 2026, 9:35 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Supplements for Controlling Resistance to Insulin

NCT00699413
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2
Interventions
nutrition education plus active supplement, nutrition education plus inactive supplement
Drug
Lead sponsor
University of Southern California
Other
Eligibility
13 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors

NCT00639262
View directory record Official record
Conditions
Brain Metastases, Primary Brain Tumors
Interventions
Sorafenib, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 6, 2026, 9:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Validation of NAD+ Measurements for Human Clinical Studies

NCT07416786
View directory record Official record
Conditions
Healthy Adults
Interventions
Oral NR Supplementation
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 6, 2026, 9:35 AM EDT
Terminated Phase 1 Interventional

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

NCT00622479
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sorafenib (Nexavar, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Maywood, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 6, 2026, 9:35 AM EDT
Terminated Phase 1 Interventional

Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

NCT00828594
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
RAD001, RAD001, sorafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 6, 2026, 9:35 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions

NCT00500045
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Interventions
nicotinic acid
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 6, 2026, 9:35 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow

NCT01085981
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%, Topical study cream, GRAS cream
Drug
Lead sponsor
East Suburban Ob Gyn
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 6, 2026, 9:35 AM EDT
Terminated Phase 3 Interventional Results available

Niacin Plus Statin to Prevent Vascular Events

NCT00120289
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Extended release niacin, Simvastatin
Drug
Lead sponsor
Axio Research. LLC
Industry
Eligibility
45 Years and older
Enrollment
3,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
68
States / cities
Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 6, 2026, 9:35 AM EDT
Terminated Phase 1 Interventional

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

NCT00734526
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide, Radiation, Sorafenib
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2018 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

"Pharmacokinetic Study of Nicotinamide Riboside"

NCT02689882
View directory record Official record
Conditions
Metabolic Disturbance
Interventions
nicotinamide riboside
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Phase 2 Interventional

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec

NCT00661180
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Nexavar (Sorafenib, BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

NCT03019666
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma, Indolent B Cell Lymphoma, Primary Mediastinal Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Phase 1 Interventional

Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

NCT00846131
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Sorafenib, Yttrium-90 (Y-90)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

NCT02135874
View directory record Official record
Conditions
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified, Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified, Recurrent Mixed Phenotype Acute Leukemia
Interventions
Clofarabine, Cytarabine, Dexamethasone, Idarubicin, Rituximab, Sorafenib, Sorafenib Tosylate, Vincristine, Vincristine Sulfate
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Phase 2 Interventional Results available

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver

NCT00906373
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Nicotinamide Riboside on Metabolism and Vascular Function

NCT03501433
View directory record Official record
Conditions
Aging, Lipemia
Interventions
Nicotinamide riboside chloride (Niagen), Placebo
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Vitamin E Supplementation in Burned Patients

NCT01749371
View directory record Official record
Conditions
Burn
Interventions
Vitamin E
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
16 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Dallas, Texas • Galveston, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 6, 2026, 9:35 AM EDT
Active, not recruiting Phase 2 Interventional

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

NCT04244630
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Antioxidants
Combination Product
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
21 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 6, 2026, 9:35 AM EDT
Terminated No phase listed Observational

PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive Disorder

NCT04353921
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
No intervention will be administered as part of this study.
Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lauderhill, Florida
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 6, 2026, 9:35 AM EDT
Completed Not applicable Interventional Results available

Alternative Options to Minimize Niacin-Induced Flushing

NCT00895193
View directory record Official record
Conditions
Hypercholesterolemia, Flushing
Interventions
Apple pectin, Aspirin 325 mg, Placebo
Other · Drug
Lead sponsor
Patrick Moriarty, MD, FACP, FACC
Other
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Oct 6, 2026, 9:35 AM EDT